



To The THSNA Award Committee and Those Whom It May Concern,

I have been passionate about hematology, specifically thrombosis and hemostasis, since medical school. After completing my residency in internal medicine and becoming a bone marrow transplant hospitalist at the Oregon Health & Science University, I knew I wanted to devote my future career to benign hematology. I plan to apply for a fellowship in hematology oncology in the next academic year, but am very grateful for the time the hospitalist year has given me to continue my contributions to the current body of literature, and to cultivate strong mentorships in the field of benign hematology.

THSNA's travel-to-a-mentor award gave me the opportunity to study under a benign hematologist that I have long since revered for his work in the field of hemostasis and thrombosis. Dr. Thomas Ortel of Duke University gained distinction for his landmark BRIDGE Trial which demonstrated that bridging anticoagulation is no more efficacious, but more hazardous in patients with atrial fibrillation undergoing elective surgery. He is also well known for his advancements in the fields of antiphospholipid antibody syndrome, heparin-induced thrombosis, malignancy-related thromboembolism, and post-thrombotic syndrome, to name a few.

During our mentorship week, I toured Duke University's platelet lab and learned the intricacies behind various laboratory techniques used to diagnosis HIT and TTP. I spent an afternoon in the apheresis clinic, gaining exposure to a large array of apheresis indications. I attended an anticoagulation meeting complete with a journal club on fixed dose PCC for vitamin K antagonist reversal. I attended a Grand Rounds on tyrosine kinase inhibitors in chronic myelogenous leukemia. I attended a hematology case conference on myeloproliferative neoplasms, each case accompanied by a corresponding hematology pathology slide. I had the honor of shadowing Dr. Ortel in his clinic, as well several of his esteemed benign hematology colleagues. I learned so much watching these doctors navigate complicated patient presentations including: suspected APS during pregnancy, hemophilia A complicated by acquired inhibitor and hemarthrosis, primary myelofibrosis complicated by symptomatic splenomegaly, management of sickle cell disease in pregnancy, and ITP complicated by hypoxic respiratory failure requiring splenectomy and ECMO.



I cannot thank THSNA enough for this opportunity, as this travel award has granted me the once in a lifetime chance to form strong mentorship bonds with a renowned. I am honored to be selected for this award, and hope the opportunity will continue for many more aspiring hematologists in the years to come.

Thank you again for this exceptional experience.

Molly Maddock Daughety, MD

Oregon Health & Science University
Assistant Professor
Bone Marrow Transplant Hospitalist
Knight Cancer Institute of Hematologic Malignancies